By EyePoint Pharmaceutics Inc.’s stock (EYPT) experienced a remarkable surge of 362% early on Monday following the company’s announcement of positive results from a Phase 2 trial of its EYP-1901 treatment for wet age-related macular degeneration (wet AMD).
Successful Trial Results
According to the company, the study successfully combined vorolanib, a selective tyrosine kinase inhibitor, with bioerodible Durasert E. The trial met its primary endpoint as well as key secondary endpoints using both doses administered, with noteworthy outcomes including:
- Over 80% reduction in treatment burden
- Nearly two-thirds of eyes remained supplement-free for up to six months
- Over 80% of patients received zero or only one supplement for up to six months
A Promising Solution for Wet AMD
Dr. Carl Regillo, Chief of Retina Service at Wills Eye Hospital, enthusiastically commented on the significance of this breakthrough: “Wet AMD is a prevalent and progressive lifetime disease. With frequent treatment, patients can maintain their visual acuity, but the unfortunate reality is that many patients end up undertreated due to the burden of dosing of the currently available, short-acting anti-VEGF therapies.”
Future Plans
EyePoint Pharmaceutics Inc. plans to release the full dataset at Angiogenesis, Exudation, and Degeneration 2024 in February. This highly anticipated event will provide further insights into the success of the Phase 2 trial.
Impressive Performance
In the year to date, EyePoint Pharmaceutics Inc.’s stock has already gained an impressive 89%. Comparatively, the S&P 500 has experienced a gain of 19.7%.
Comments